logo

Intellia Therapeutics, Inc. (NTLA)



Trade NTLA now with
  Date
  Headline
6/1/2020 7:02:19 AM Regeneron And Intellia To Co-develop Potential Hemophilia A And B Treatments
5/7/2020 7:53:20 AM Intellia Therapeutics Q1 Loss/Shr $0.63 vs Loss $0.49 Prior Year
3/31/2020 7:44:00 AM Intellia Therapeutics: FDA Accepts IND Application For CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate
8/2/2019 7:57:38 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) FY19 Rev. Estimate To 41.6 M From 30.0 M
8/2/2019 7:57:27 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) Q4 19 Rev. Estimate To 10.0 M From 7.5 M
8/2/2019 7:57:17 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q3 19 Rev. Estimate To 10.0 M From 7.5 M
8/2/2019 7:56:55 AM Wedbush Is Lowering Intellia Therapeutics, Inc. (NTLA) FY19 Estimate To -2.29 From -1.84
8/2/2019 7:56:42 AM Wedbush Is Cutting Intellia Therapeutics, Inc. (NTLA) Q4 19 Estimate To -0.63 From -0.44
8/2/2019 7:56:28 AM Wedbush Is Lowering Intellia Therapeutics, Inc. (NTLA) Q3 19 Estimate To -0.61 From -0.43
8/2/2019 7:56:00 AM Wedbush Reiterates Intellia Therapeutics, Inc. (NTLA) At Outperform With $21 Price Target
5/3/2019 8:39:25 AM Wedbush Raises Intellia Therapeutics, Inc. (NTLA) To Outperform From Neutral With $21 Up From $20 Price Target
12/6/2018 7:34:31 AM Intellia Therapeutics And Novartis Expand Cell Therapy Collaboration
11/2/2018 6:31:35 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) FY19 Estimate To -1.18 From -1.94
11/2/2018 6:31:13 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q4 19 Estimate To -0.48 From -0.52
11/2/2018 6:30:56 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q3 19 Estimate To -0.35 From -0.49